Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.
8 signals in the last 90 days.
The order this company entered each market — oldest to newest
Ascletis Presents Obesity Treatment Pipeline at ADA
Ascletis Presents Obesity Pipeline at ADA
Sign up to see the full signal feed
How Ascletis Pharma Inc.'s international expansion compares to its competitors
Ascletis Pharma Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Ascletis Pharma Inc.You | 2 | 1 | -67% | 8 | 7 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Ascletis' ASC30 depot formulation shows significant weight loss of 7.5% after 3 monthly doses, with effects lasting up to 4 months, potentially enabling quarterly maintenance therapy.
Ascletis' ASC30 subcutaneous depot formulation achieved 7.5% weight loss at week 16, maintained for 4 months after final dose, suggesting potential for monthly treatment and quarterly maintenance therapy.
Ascletis' ASC30 depot formulation shows significant weight loss of 7.5% after 3 monthly doses, with effects lasting up to 4 months, potentially enabling quarterly maintenance therapy.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Ascletis Pharma Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
